MicroRNA-31-3p/RhoA signaling in the dorsal hippocampus modulates methamphetamine-induced conditioned place

Hongyan Qian1,2, Qing Shang1,2, Min Liang1,2

  • 1Institute of Forensic Injury, Institute of Forensic Bio-Evidence, Western China Science and Technology Innovation Harbor, Xi'an Jiaotong University, Xi'an, People's Republic of China.

Psychopharmacology
|July 27, 2021
PubMed
Abstract

Insights

The miR-31-3p/RhoA pathway in the dorsal hippocampus influences methamphetamine addiction behaviors. Modulating this epigenetic pathway offers potential therapeutic targets for treating METH addiction.

Area of Science:

  • Neuroscience
  • Epigenetics
  • Molecular Biology

Background:

  • MicroRNAs (miRNAs) regulate neuroplasticity and are linked to methamphetamine (METH) addiction.
  • RhoA, a small Rho GTPase, is crucial for synaptic plasticity and addictive behaviors.
  • The precise relationship between RhoA and miRNAs involved in METH addiction is not fully understood.

Purpose of the Study:

  • To investigate the molecular and epigenetic mechanisms of the miR-31-3p/RhoA pathway in the context of METH addiction.
  • To determine if miR-31-3p directly targets RhoA and its role in METH-induced behaviors.

Main Methods:

  • Detected RhoA protein and miR-31-3p levels in the dorsal hippocampus (dHIP) of mice.
  • Utilized a dual luciferase reporter assay to confirm RhoA as a direct target of miR-31-3p.
  • Employed adeno-associated virus (AAV) vectors for knockdown or overexpression of miR-31-3p and RhoA in the dHIP, followed by conditioned place preference (CPP) testing.

Main Results:

  • RhoA protein levels decreased while miR-31-3p increased in the dHIP of METH-exposed mice.
  • miR-31-3p directly targets RhoA.
  • Modulating miR-31-3p or RhoA in the dHIP significantly altered METH-induced CPP, with effects specific to METH, not general reward behaviors.

Conclusions:

  • The miR-31-3p/RhoA pathway in the dHIP plays a critical role in modulating METH-induced addictive behaviors.
  • Epigenetic mechanisms involving non-coding RNAs like miR-31-3p represent promising therapeutic avenues for METH addiction treatment.

Related Concept Videos